GBI Research, the leading business intelligence provider, has released its
latest research, “Early Stage Drug Discovery in Disease Segments -
Innovation Focuses on Stem Cell Therapies and Gene Therapies”. It
provides an in-depth analysis of the unmet needs, drivers and barriers that
affect the global Central Nervous System Disorders (CNS), Metabolic Disorders,
Immunologic Disorders, Infection, Cardiovascular Disease and Oncology
therapeutic markets. The report analyzes the early stage drug development that
includes drugs under development in the discovery and preclinical stages of
development for the above mentioned indications in the US, the top five
countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.
Treatment usage patterns, sales value and the annual cost of therapy are
forecast until 2017 for the key geographies in the leading therapeutic
segments. Further, the report provides competitive benchmarking for the
leading companies and analyzes the Mergers and Acquisitions (M&A) and
licensing agreements that shape the global market.
The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research’s team of industry experts.
Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline
Early stage drug development includes drugs under development in the discovery
and preclinical stages of development. These studies are conducted in order to
assess the safety and efficacy of the drug. This stage of development plays a
key role in drug development as it determines potential molecules to be
further processed for development by different companies. Increased strategies
like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug
Administration) are persuading companies to implement safety scrutiny measures
at early stages of development.
The majority of the molecules in the early stages of development are being
developed for cancer indications. Molecules under development for breast
cancer account for 23% of the total early stage development molecules under
development for cancer. This is followed by prostate cancer, accounting for
20%, followed by colon cancer (15%).
Other than Oncology, other therapeutic areas with high activity in Research
and Development (R&D) in early development phases include Central Nervous
System (CNS) disorders, immunological disorders, and metabolic disorders. CNS
disorders accounted for 14% of early stage drugs under development, followed
by immunological disorders (13%) and metabolic disorders (10%). Compared to
other therapeutic areas, there is less R&D activity in the metabolic disorders
(9%) and infectious disease (9%) segments.
Breast Cancer Therapeutics Leads the Early Stage Drug Developmental Pipeline;
Immunotherapy accounts for 33% of the Drug Classes Under Development
The breast cancer early stage pipeline consists of 141 molecules, with 22
molecules in the discovery phase and 119 molecules in the preclinical phase.
These molecules are in development for the treatment of patients suffering
with breast cancer. The discovery phase of the breast cancer pipeline consists
of 16% of the molecules and the preclinical phase consists of 84% of the
pipeline.
The early stage breast cancer therapeutics pipeline has been supplemented by
novel therapeutic molecules. Immunotherapy, with 47 molecules, contributes 33%
of the pipeline. Protein receptor targetors contribute 16%. Enzyme inhibitors
contribute 12% of the pipeline. Vaccines contribute 8% of the pipeline. Gene
therapy contributes 5% of the pipeline. Apoptosis targetors contribute to 3%.
Chemotherapy, angiogenic antagonists, stem cell therapy and hormones with two
molecules each contribute 1%. Combination therapy, with three molecules,
contributes 2%. Cellular motility inhibitors, synthetic picolinic
ester-substituted retinoids, microtubule inhibitors with one molecule each
contribute to 1% each. Few drugs with the mechanisms of action apart from
these major classes contribute to 13% of the pipeline.
Key Players in the Early Stage Drug Development Pipeline are Hanall
Pharmaceutical, Patrys and F. Hoffman La Roche
In early stage drug development, as in, drugs in the discovery and preclinical
phases of development, the key players were identified to be Hanall
Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffman La Roche, Mirna
Therapeutics and Aphios Corporation. These key players showed immense activity
in R&D in the early stages of drug development in different therapeutic areas
like CNS, cardiovascular diseases, oncology, infection, immunological
disorders and metabolic disorders. Hanall Pharmaceuticals has 39 molecules in
discovery as well as preclinical stage Parkinson’s disease, diabetes,
Alzheimer’s disease, hepatitis, allergy and hypertension. Patrys
Limited has 19 molecules in development in the discovery and preclinical
stages of development in different therapeutic segments like ovarian cancer,
lung cancer and colon cancer. Roche has 17 molecules in development in the
discovery and preclinical stages of development in different therapeutic
segments like prostate cancer, lung cancer, melanoma, breast cancer, colon
cancer, schizophrenia, obesity and Human Immunodeficiency Virus (HIV) that
causes Acquired Immunodeficiency Syndrome (AIDS).
Summary
GBI Research’s new report, “Early Stage Drug Development in
Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene
Therapies”, provides an in-depth analysis of the unmet needs, drivers
and barriers that affect the global Central Nervous System Disorders (CNS),
Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease
and Oncology therapeutic markets. The report analyzes the early stage drug
development that includes drugs under development in the discovery and
preclinical stages of development for the above mentioned indications in the
US, the top five countries in Europe (the UK, Germany, France, Italy and
Spain) and Japan. Treatment usage patterns, sales value and the annual cost of
therapy are forecast until 2017 for the key geographies in the leading
therapeutic segments. Further, the report provides competitive benchmarking
for the leading companies and analyzes the Mergers and Acquisitions (M&A) and
licensing agreements that shape the global market.
The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research’s team of industry experts.
GBI Research finds that early stage drug development includes drugs under
development in the discovery and preclinical stages of development. These
studies are conducted in order to assess the safety and efficacy of the drug.
This stage of development plays a key role in drug development as it
determines potential molecules to be further processed for development by
different companies. Increased strategies like RAS (Risk Assessment
Strategies) issued by the US FDA (Food and Drug Administration) are persuading
companies to implement safety scrutiny measures at early stages of
development.
The majority of the molecules in the early stages of development are being
developed for cancer indications. Molecules under development for breast
cancer account for 23% of the total early stage development molecules under
development for cancer. This is followed by prostate cancer, accounting for
20%, followed by colon cancer (15%).
Other than Oncology, other therapeutic areas with high activity in Research
and Development (R&D) in early development phases include Central Nervous
System (CNS) disorders, immunological disorders, and metabolic disorders. CNS
disorders accounted for 14% of early stage drugs under development, followed
by immunological disorders (13%) and metabolic disorders (10%). Compared to
other therapeutic areas, there is less R&D activity in the metabolic disorders
(9%) and infectious disease (9%) segments.
Scope
The scope of this report includes - • Coverage of pipeline molecules
in various discovery and pre-clinical phases of drug development along with
pipeline analysis of the leading therapeutic segments, including Oncology, CNS
disorders, immunological disorders, infection, metabolic disorders and
cardiovascular disorders. • Analysis of the above mentioned disorders
market in the leading geographies of the world, which are the US, the UK,
Germany, France, Italy, Spain and Japan. • Key drivers and barriers
that have a significant impact on the market. • Competitive
benchmarking of leading companies. The key companies studied in this report
are Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffmann-La Roche Ltd,
Mirna Therapeutics, Inc. and Aphios Corporation. • Key M&A activities
and licensing agreements that have taken place between 2005 and 2010 in the
global Oncology, CNS disorders, immunological disorders, infection, metabolic
disorders and cardiovascular disorders markets.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- • Align your product portfolio to the markets with high growth
potential. • Develop market-entry and market expansion strategies by
identifying the leading therapeutic segments and geographic markets poised for
strong growth. • Reinforce R&D pipelines by identifying new target
mechanisms which can produce first-in-class molecules with more efficiency and
better safety. • Develop key strategic initiatives by understanding
the key focus areas of leading companies. • Exploit in-licensing and
out-licensing opportunities by identifying products that could fill portfolio
gaps.
Table of Contents
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Early Stage Drug Discovery in Disease Segments - Introduction
2.1 GBI Research Report Guidance
3. Early Stage Drug Discovery in Disease Segments - Overview
3.1 Drug Discovery and Development
3.1.1 Drug Development-Stages
3.2 Early Stage Drug Discovery Studies- An overview
3.3 Early Stage Drug Discovery Design and Planning
3.3.1 Early Stage Drug Discovery - Strategic Planning
3.3.2 Key Considerations During Early Stage Drug Discovery
4. Early Stage Drug Discovery in Disease Segments - Technology Landscape
4.1 Current System
4.1.1 Overview
4.1.2 Key Technologies
4.1.3 In-vitro ADMET Screening Models
4.1.4 In vivo ADMET Screening Models
4.1.5 In silico ADMET Screening models
4.2 Trends in Technology Models
4.2.1 Recent Technology Developments
5. Early Stage Drug Discovery in Disease Segments - Drug Discovery and Development - A Challenge to Pharmaceutical Companies
5.1 Drug Discovery & Development Process
5.1.1 Drug Discovery Process
6. Early Stage Drug Discovery in Therapeutic Segments
6.1 Central Nervous System Disorders
6.1.1 Alzheimer's disease
6.1.2 Parkinson's disease
6.1.3 Multiple Sclerosis
6.1.4 Schizophrenia
6.2 Metabolic Disorders
6.2.1 Diabetes
6.2.2 Obesity
6.3 Immunological Disorders
6.3.1 Rheumatoid Arthritis
6.3.2 Crohn's Disease
6.3.3 Systemic Lupus Erythematosus (SLE)
6.3.4 Allergy
6.4 Infections
6.4.1 HIV/AIDS
6.4.2 Hepatitis A, B, C
6.5 Cardiovascular Diseases
6.5.1 Hypertension
6.5.2 Dyslipidemia
6.5.3 Pulmonary Arterial Hypertension (PAH)
6.5.4 Myocardial Infarction
6.6 Oncology
6.6.1 Bladder Cancer
6.6.2 Lung Cancer
6.6.3 Non-Small Cell Lung Cancer (NSLC)
6.6.4 Breast Cancer
6.6.5 Colon Cancer
6.6.6 Melanoma
6.6.7 Ovarian Cancer
6.6.8 Prostate Cancer
7. Early Stage Drug Discovery in Disease Segments - Top Five Pharmaceutical Players in Early Stage Drug Discovery
7.1 Introduction
7.2 Hanall Pharmaceutical
7.2.1 Company Overview
7.2.2 Pipeline
7.3 Patrys Limited
7.3.1 Company Overview
7.3.2 Pipeline
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.2 Pipeline
7.5 Mirna Therapeutics
7.5.1 Company Overview
7.5.2 Pipeline
7.6 Aphios Corporation
7.6.1 Company Overview
7.6.2 Pipeline
8. Early Stage Drug Discovery in Disease Segments - Strategic Consolidations
8.1 R&D Licensing Agreements
8.1.1 Deals by Indication
8.1.2 Deals by Geography
8.1.3 Deal Summaries by Therapeutic Class
9. Early Stage Drug Discovery in Disease Segments - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
List of Tables:
Table 1: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Alzheimer's Disease, December 2010
Table 2: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Parkinson's Disease, December 2010
Table 3: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Multiple Sclerosis, December 2010
Table 4: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Schizophrenia, December 2010
Table 5: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Diabetes, December 2010
Table 6: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Obesity, December 2010
Table 7: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Rheumatoid Arthritis Therapeutics, December 2010
Table 8: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Crohn's Disease, December 2010
Table 9: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in SLE, December 2010
Table 10: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Allergy, December 2010
Table 11: Early Stage Drug Discovery in Disease Segments, Global, Patent
Expiries of Major Marketed Drugs in HIV/AIDS, December 2010
Table 12: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in HIV/AIDS, December 2010
Table 13: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Hepatitis Therapeutics, December 2010
Table 14: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Hypertension Therapeutics, December 2010
Table 15: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics, December 2010
Table 16: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in PAH Therapeutics, December 2010
Table 17: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in PAH Therapeutics (%), December 2010
Table 18: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Myocardial Infarction Therapeutics, December
2010
Table 19: Early Stage Drug Discovery in Disease Segments, Bladder Cancer
Therapeutics, Prevalence by Country, 2009
Table 20: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics, December 2010
Table 21: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Bladder Cancer Therapeutics (%), December 2010
Table 22: Early Stage Drug Discovery in Disease Segments, Lung Cancer
Categorized by Disease Stage, December 2010
Table 23: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Lung Cancer Therapeutics, December 2010
Table 24: Early Stage Drug Discovery in Disease Segments, Global, NSCLC
Treatment by Stage of the Disease, December 2010
Table 25: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in NSLC Therapeutics, December 2010
Table 26: Early Stage Drug Discovery in Disease Segments, Breast Cancer
Stage Classification, December 2010
Table 27: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Breast Cancer, December 2010
Table 28: Early Stage Drug Discovery in Disease Segments, Global, Global,
Staging of Colon Cancer, December 2010
Table 29: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Colon Cancer Therapeutics, December 2010
Table 30: Early Stage Drug Discovery in Disease Segments, Global, Staging
of Melanoma, December 2010
Table 31: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Melanoma, December 2010
Table 32: Early Stage Drug Discovery in Disease Segments, Global, Staging
of Ovarian Cancer, December 2010
Table 33: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics, December 2010
Table 34: Early Stage Drug Discovery in Disease Segments, Global, Staging
of Prostate Cancer, December 2010
Table 35: Early Stage Drug Discovery in Disease Segments, Global, Early
Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics, December 2010
Table 36: Early Stage Drug Discovery in Disease Segments, Hanall
Pharmaceutical - Pipeline Products, December 2010
Table 37: Early Stage Drug Discovery in Disease Segments, Patrys Limited -
Pipeline Products, December 2010
Table 38: Early Stage Drug Discovery in Disease Segments, F. Hoffmann-La
Roche Ltd. - Pipeline Products, December 2010
Table 39: Early Stage Drug Discovery in Disease Segments, Mirna
Therapeutics, Inc. - Pipeline Products, December 2010
Table 40: Early Stage Drug Discovery in Disease Segments, Aphios
Corporation, Inc. - Pipeline Products, December 2010
Table 41: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Therapeutic Class, Metabolic Disorders (%), 2005-2010
Table 42: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Therapeutic Class, Immunological Disorders (%), 2005-2010
Table 43: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Therapeutic Class, Cardiovascular Disorders (%), 2005-2010
Table 44: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Therapeutic Class, Infections, 2005-2010
Table 45: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Therapeutic Class, Oncology, 2005-2010
Table 46: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Therapeutic Class, Central Nervous System Disorders, 2005-2010
List of Figures
Figure 1: Early Stage Drug Discovery in Disease Segments, Series of
Research Activities Leading to Drug Discovery, December 2010
Figure 2: Early Stage Drug Discovery in Disease Segments, Stages of Drug
Development, December 2010
Figure 3: Early Stage Drug Discovery in Disease Segments, Preclinical
ADMET Studies, December 2010
Figure 4: Early Stage Drug Discovery in Disease Segments, Recent
Technological Developments in Early Stage Development, December 2010
Figure 5: Early Stage Drug Discovery in Disease Segments by Therapy,
December 2010
Figure 6: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Different Therapeutic Segments December 2010
Figure 7: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
pipeline in Alzheimer's Disease (%), December 2010
Figure 8: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Alzheimer's Disease (%), December 2010
Figure 9: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Parkinson's Disease (%), December 2010
Figure 10: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Parkinson's Disease (%), December 2010
Figure 11: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Multiple Sclerosis (%), December 2010
Figure 12: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Multiple Sclerosis (%), December 2010
Figure 13: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Schizophrenia (%), December 2010
Figure 14: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Schizophrenia (%), December 2010
Figure 15: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
pipeline in Diabetes (%), December 2010
Figure 16: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Diabetes (%), December 2010
Figure 17: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Obesity (%), December 2010
Figure 18: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Obesity (%), December 2010
Figure 19: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Rheumatoid Arthritis Therapeutics (%), December 2010
Figure 20: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Rheumatoid Arthritis (%), December 2010
Figure 21: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in Crohn's Disease (%), December 2010
Figure 22: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Crohn's Disease (%), December 2010
Figure 23: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in SLE (%), December 2010
Figure 24: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in SLE (%), December 2010
Figure 25: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Allergy(%), December 2010
Figure 26: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Allergy (%), December 2010
Figure 27: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline in HIV/AIDS Therapeutics (%), December 2010
Figure 28: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in HIV/AIDS (%), December 2010
Figure 29: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Hepatitis Therapeutics (%), December 2010
Figure 30: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Hepatitis Therapeutics (%), December 2010
Figure 31: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
pipeline by Phase in Hypertension Therapeutics (%), December 2010
Figure 32: Early Stage Drug Discovery in Disease Segments , Early Stage
R&D Pipeline by Mechanism of Action in Hypertension Therapeutics (%), December
2010
Figure 33: Early Stage Drug Discovery in Disease Segments , Early Stage
R&D Pipeline by Phase in Dyslipidemia Therapeutics (%), December 2010
Figure 34: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Dyslipidemia Therapeutics (%), December 2010
Figure 35: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in PAH (%), December 2010
Figure 36: Early Stage Drug Discovery in Disease Segments , Early Stage
R&D Pipeline by Phase in Myocardial Infarction (%), December 2010
Figure 37: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Myocardial Infarction (%), December 2010
Figure 38: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Bladder Cancer Therapeutics (%), December
2010
Figure 39: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Lung Cancer Therapeutics (%), December 2010
Figure 40: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Lung Cancer Therapeutics (%), December 2010
Figure 41: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in NSLC Therapeutics (%), December 2010
Figure 42: Early Stage Drug Discovery in Disease Segments , Early Stage
R&D Pipeline by Mechanism of Action in NSLC Therapeutics (%), December 2010
Figure 43: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Breast Cancer Therapeutics (%), December 2010
Figure 44: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Breast Cancer Thereapeutics (%), December
2010
Figure 45: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Colon Cancer Therapeutics (%), December 2010
Figure 46: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Colon Cancer Therapeutics (%), December 2010
Figure 47: Early Stage Drug Discovery in Disease Segments , Early Stage
R&D Pipeline by Phase in Melanoma Therapeutics (%), December 2010
Figure 48: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Melanoma Therapeutics (%), December 2010
Figure 49:Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Ovarian Cancer Therapeutics (%), December 2010
Figure 50: Early Stage Drug Discovery in Disease Segments , Early Stage
R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics(%),
December 2010
Figure 51: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Phase in Prostate Cancer Therapeutics (%), December 2010
Figure 52: Early Stage Drug Discovery in Disease Segments, Early Stage R&D
Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics (%), December
2010
Figure 53: Early Stage Drug Discovery in Disease Segments, Top Five
Pharmaceutical Players in Early Stage Drug Develpment, December 2010
Figure 54: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Indication (%), 2005-2010
Figure 55: Early Stage Drug Discovery in Disease Segments, Major Licensing
Agreements by Geography (%), 2005-2010
China Pharmaceutical Guidebook Series (3) 2013 - Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products
